XML 85 R59.htm IDEA: XBRL DOCUMENT
v3.24.1

Grant and Awards (Narrative) (Details) - USD ($) $ in Thousands |  |  |  | 12 Months Ended
--- | --- | --- | --- | ---
Sep. 29, 2022 | Jun. 15, 2020 | Mar. 13, 2020 | Dec. 31, 2023 | Dec. 31, 2022
Award [Line Items] |  |  |  |  |
Revenue from grants |  |  |  | $ 4,529 | $ 5,508
Medical Technology Enterprise Consortium [Member] |  |  |  |  |
Award [Line Items] |  |  |  |  |
Revenue from grants | $ 16,300 | $ 15,000 |  | 4,500 | 5,500
Increase in expected revenue from grants | $ 1,300 |  |  |  |
Unbilled award receivable |  |  |  | 1,500 | 1,900
Cystic Fibrosis Foundation [Member] |  |  |  |  |
Award [Line Items] |  |  |  |  |
Research and development benefit |  |  |  | 300 | $ 1,000
Award receivable |  |  | $ 1,000 | $ 300 |
Award agreement interruption period |  |  | 360 days |  |
Maximum [Member] | Cystic Fibrosis Foundation [Member] |  |  |  |  |
Award [Line Items] |  |  |  |  |
Amount of threshold development award |  |  | $ 5,000 |  |

X
- Definition Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product. + References No definition available. + Details
Name: | armp_AwardAgreementInterruptionPeriod
Namespace Prefix: | armp_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents about award line items. + References No definition available. + Details
Name: | armp_AwardLineItems
Namespace Prefix: | armp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The carrying amount as of the balance sheet date of award receivable. + References No definition available. + Details
Name: | armp_AwardReceivable
Namespace Prefix: | armp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase (decrease) in expected revenue that is not accounted for under Topic 606, classified as other. + References No definition available. + Details
Name: | armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther
Namespace Prefix: | armp_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate benefit incurred during the reporting period as a result of research and development activities. + References No definition available. + Details
Name: | armp_ResearchAndDevelopmentBenefit
Namespace Prefix: | armp_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The threshold amount of development award under the award agreement. + References No definition available. + Details
Name: | armp_ThresholdDevelopmentAward
Namespace Prefix: | armp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Unbilled award receivable. + References No definition available. + Details
Name: | armp_UnbilledAwardReceivable
Namespace Prefix: | armp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of revenue that is not accounted for under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RevenueNotFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=armp_MedicalTechnologyEnterpriseConsortiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=armp_CysticFibrosisFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |